A more rapid disease improvement was observed in the IL2 group. Collectively study provided evidence that low-dose IL2 coupled with standard therapy might be effective and well tolerated in patients with SLE compared to standard therapy alone. Here, IL2 is linked to systemic lupus erythematosus.